Belite Bio Submits Japanese New Drug Application For Tinlarebant In Stargardt Disease Type 1
Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss.
Belite Bio asked Japanese regulators to approve a new medicine called tinlarebant that might help people with a rare eye disease that makes them lose their sight over time. This is a big step forward for the company, so watch to see if regulators say yes—that would mean the medicine could actually help patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.